SCHEMBL5409651

SCHEMBL5409651

COc1ccccc1/C=C/S(=O)(=O)NC(=O)c1ccc(Cl)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 6/20 0.49
FLT4 P35916 6/20 0.49
KDR P35968 6/20 0.49
LMNA P02545 2/20 0.48
NPC1 O15118 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
PTGES2 Q9H7Z7 4/20 0.47
NFE2L2 Q16236 4/20 0.46
ALDH1A1 P00352 1/20 0.46
ANO1 Q5XXA6 1/20 0.45
ALOX5 P09917 1/20 0.43
PTGS1 P23219 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409664 1.00 FLT1 (0.49) FLT1FLT4KDRLMNANPC1
SCHEMBL4618139 0.90 FLT1 (0.55) FLT1FLT4KDRLMNANPC1
SCHEMBL4618131 0.90 FLT1 (0.55) FLT1FLT4KDRLMNANPC1
SCHEMBL5424981 0.89 ABCB1 (0.46) FLT1FLT4KDRNPC1PTGES2
SCHEMBL5424991 0.89 ABCB1 (0.46) FLT1FLT4KDRNPC1PTGES2
SCHEMBL5416377 0.87 AR (0.49) FLT1FLT4KDRLMNANPC1
SCHEMBL5416384 0.87 AR (0.49) FLT1FLT4KDRLMNANPC1
SCHEMBL5421004 0.86 FLT1 (0.53) FLT1FLT4KDRMAPTPTGES2
SCHEMBL5420993 0.86 FLT1 (0.53) FLT1FLT4KDRMAPTPTGES2
SCHEMBL5416926 0.83 PTGES2 (0.53) FLT1FLT4KDRPTGES2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 FLT1 4126/4885FLT4 4438/4885KDR 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.